Stimulants

RespireRx Pharmaceuticals Inc. to Participate in Upcoming January Virtual Investor Conferences

Retrieved on: 
Friday, January 8, 2021

From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.

Key Points: 
  • From our ampakine platform, our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials.
  • Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
  • Epilepsy is a chronic and highly prevalent neurological disorder that affects millions of people world-wide.
  • We believe that the medical and patient community are in clear agreement that there is desperate need for improved antiepileptic drugs.

Millennium Health Study Reveals Nationwide Increase in Urine Drug Test Positivity for Methamphetamine

Retrieved on: 
Tuesday, January 5, 2021

SAN DIEGO, Jan. 5, 2021 /PRNewswire/ --A study conducted by Millennium Health and published in the Journal of Addiction Medicine reveals a dangerous increase in definitive urine drug test positivity for methamphetamine alone and in combination with other substances.

Key Points: 
  • SAN DIEGO, Jan. 5, 2021 /PRNewswire/ --A study conducted by Millennium Health and published in the Journal of Addiction Medicine reveals a dangerous increase in definitive urine drug test positivity for methamphetamine alone and in combination with other substances.
  • Additionally, the combination of methamphetamine with other substances increases the risk of poor health outcomes, including overdose."
  • This study highlights the rising positivity rates of methamphetamine across the country and the need to carefully evaluate patients for polysubstance use to tailor and adjust treatment plans.
  • Millennium Health is an accredited specialty laboratory with over a decade of experience delivering timely, accurate, clinically-actionable information through our nationwide medication monitoring and drug testing services .

Adamas Completes Acquisition of OSMOLEX ER®

Retrieved on: 
Tuesday, January 5, 2021

Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy with or without concomitant dopaminergic medications.

Key Points: 
  • Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy with or without concomitant dopaminergic medications.
  • OSMOLEX ER (amantadine) extended-release tablets is FDA-approved for the treatment for Parkinsons disease and drug-induced extrapyramidal reactions in adult patients.
  • According to their Prescribing Information, neither GOCOVRI nor OSMOLEX ER are interchangeable with other amantadine immediate- or extended-release products for their respective approved indications.
  • OSMOLEX ER, (amantadine) extended-release tablets, is FDA-approved for the treatment of Parkinsons disease and drug-induced extrapyramidal reactions in adult patients.

Tobacco Alternative Gums Market 2020-2024 - Featuring Alchem International Pvt. Ltd., Cambrex Corp., Cipla Inc., Among Others to Contribute for the Market Growth

Retrieved on: 
Wednesday, December 23, 2020
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201223005579/en/
    Technavio has announced its latest market research report titled Global Tobacco Alternative Gums Market 2020-2024 (Graphic: Business Wire)
    Worried about the impact of COVID-19 on your Business?
  • The report on the tobacco alternative gums market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The tobacco alternative gums market analysis includes type segment and geography landscape.
  • This study identifies the rising prices of cigarettes as one of the prime reasons driving the tobacco alternative gums market growth during the next few years.

KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder

Retrieved on: 
Tuesday, December 22, 2020

KemPharm is developing KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD).

Key Points: 
  • KemPharm is developing KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD).
  • If the KP879 IND filing is accepted by the FDA, KemPharm intends to initiate efficacy studies of KP879 in 2021.
  • It is anticipated that certain data from previously completed KP415 research may be leveraged for KP879, including pharmacokinetic studies, which KemPharm believes could potentially streamline the development timeline of KP879.
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.

Next Generation Labs LLC expands TFN® non-tobacco synthetic nicotine distribution and intellectual property protection rights in USA, Europe and Asia

Retrieved on: 
Thursday, December 17, 2020

With demand for authenticated synthetic nicotine growing, Next Generation Labs notes that "TFN non-tobacco derived synthetic nicotine has increasingly become the industry benchmark for both quality and consumer acceptance in many branded nicotine alternative products in the US market, select European countries, and in emerging novel-nicotine markets in Asia."

Key Points: 
  • With demand for authenticated synthetic nicotine growing, Next Generation Labs notes that "TFN non-tobacco derived synthetic nicotine has increasingly become the industry benchmark for both quality and consumer acceptance in many branded nicotine alternative products in the US market, select European countries, and in emerging novel-nicotine markets in Asia."
  • In China, Next Generation Labs is working closely with trusted vape device manufacturers, such as ITSUWA, to deliver authorized TFN formulations into vape devices for sales worldwide.
  • In India, Dholakia PVT is formulating TFN nicotine into manufactured white label nicotine portion pouch products for customers in the USA and Europe.
  • Further, Next Generation Labs remains intent on protecting its TFN global intellectual property assets, and on enforcing its IP rights under international, national and local laws against infringers and marketers falsely claiming to manufacture TFN nicotine, or falsely claiming to be using TFN in their products.

Grey Cloak Tech Releases Study of Fuel4Thought Brain Booster

Retrieved on: 
Tuesday, December 8, 2020

Fuel4Thought Brain Booster Provides Astounding Brain Activation Improvement of 49% with Its Revolutionary 2.5 oz Formulation with Zero Caffeine, Zero Sugar and Zero Crash

Key Points: 
  • Fuel4Thought Brain Booster Provides Astounding Brain Activation Improvement of 49% with Its Revolutionary 2.5 oz Formulation with Zero Caffeine, Zero Sugar and Zero Crash
    LAS VEGAS, NV, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire Grey Cloak Tech Inc. (OTCQB: GRCK ) (soon to be Healthy Extracts Inc .
  • Dr. James Rouse, Medical Advisory Board President and renowned Iron Man Triathlete, said: Fuel4Thought is the varsity of brain nutrition.
  • F4T Brain Booster provides the best nourishment possible without the negative ingredients of sugar and caffeine.
  • It reduces inflammation in the brain, energizes the brain, sharpens focus, enhances memory, improves concentration, and increases productivity.

KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA

Retrieved on: 
Wednesday, December 2, 2020

KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.

Key Points: 
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.
  • KemPharms co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

Adamas Announces Agreement to Settle Patent Litigation with Osmotica

Retrieved on: 
Wednesday, December 2, 2020

Adamas current portfolio consists of GOCOVRI (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy.

Key Points: 
  • Adamas current portfolio consists of GOCOVRI (amantadine) extended-release capsules for the treatment of dyskinesia in patients with Parkinsons disease receiving levodopa-based therapy.
  • This settlement agreement removes any further litigation costs and related distraction for Adamas.
  • The different FDA-approved indications and pharmacokinetic profiles for GOCOVRI and OSMOLEX ER allow for the treatment of distinct patient populations.
  • Adamas undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event

Retrieved on: 
Monday, November 30, 2020

KemPharms prodrug product candidate pipeline is focused on the high need areas of ADHD and stimulant use disorder.

Key Points: 
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of ADHD and stimulant use disorder.
  • KemPharms co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .